{"date":"2026-08-22","count":1,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-6467-2026-08-22-0443-1kx7kvf","company_id":"6467","company":"泰合","market":"興櫃","industry":"生技醫療","date":"2026-08-22","time":"04:43:42","subject":"公告本公司TAH3311抗血栓口溶膜新劑型新藥之美國新藥查驗登記申請(NDA)進入實質審查","clause":"第44款","fact_date":"2026-08-22","cite_as":"公開資訊觀測站重大訊息：泰合（6467），2026-08-22 04:43，「公告本公司TAH3311抗血栓口溶膜新劑型新藥之美國新藥查驗登記申請(NDA)進入實質審查」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}